All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
Acute myeloid leukemia (AML) is a malignant cancer characterized by the infiltration of bone marrow by proliferative, abnormally differentiated, heterogeneous, clonal hematopoietic stem cells (HSCs), leading to bone marrow failure, and ultimately death if untreated.1
These abnormal white blood cells progressively occupy the bone marrow niche, where healthy HSCs ordinarily reside and are maintained.2 Emerging evidence suggests that leukemic cells induce molecular changes in hematopoietic cells, contributing to the transformation of the normal bone marrow niche into a ‘leukemia’ niche, allowing the growth and proliferation of leukemic cells, disrupting the ordinary functioning of HSCs.3
To classify the disease, morphological assessments are carried out on bone marrow and the blood is analyzed for the expression of cytoplasmic markers using flow cytometry.4 Major categories of AML include therapy-related AML, AML with myelodysplasia-related changes, AML with recurrent genetic abnormalities and AML otherwise not specified.5
Current therapies include induction therapy, consolidation therapy and allogeneic hematopoietic stem cell transplantation (allo-HSCT), with those ineligible for intensive therapy receiving supportive care, low-dose cytarabine and the hypomethylating agents, azacitidine and decitabine. Targeted therapy drugs have also been introduced in recent years, with a ficus on FLT3 and IDH inhibitors.
The AML Global Portal has reported on drugs that have recently been approved, or are in the process of being approved:
Over the last year, the AML Global Portal has reported on drug approvals around the world:
Despite the development of optimal therapeutic approaches, such as intensive chemotherapy and allogeneic HSC transplantation, only a minority of patients are cured successfully. Thus, designing and developing more effective therapeutic approaches, that target key molecular mechanisms driving pathogenesis, to improve clinical outcomes is desirable.
Please visit www.know-aml.com for more information about AML World Awareness Day.
"How I treat": case studies to address new challenges encountered in the treatment of AML
The “How I Treat” series in Blood aims to offer diagnostic or therapeutic advice for a disease or several distinct aspects of a single disorder. There have been...
August 2019 | Druggable mutations in AML
This month's educational theme in acute myeloid leukemia surrounds druggable muations. Here, we summarise our past content on this theme.
Subscribe to get the best content related to AML delivered to your inbox